Food and Drug Administration (FDA) for its Supplemental Abbreviated New Drug Application (ANDA) for its Fentanyl Transdermal System
The objective of the present study was to compare constipation rates across three long-acting opioids: fentanyl transdermal system
, oxycodone HCI controlled-release (CR), and morphine CR.
Fentanyl transdermal system
should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system
Anyone who has 100 mcg/hr Fentanyl Transdermal System
patches should check the box or foil pouch for the lot number and expiration date to see if they have patches that are being recalled.
Watson Announces Limited Recall of Fentanyl Transdermal System
confirmed today that its matrix design Fentanyl Transdermal System
(FTS) is not part of the widespread recall being conducted by Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Food & Drug Administration to market Fentanyl Transdermal System
Food and Drug Administration (FDA) for its fentanyl transdermal system
, which is bioequivalent to Alza Corporation's Duragesic(R).
Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for fentanyl transdermal system
in the 25, 50, 75 & 100 mcg/hour strengths.
Food and Drug Administration has granted final approval for Mylan Technologies' Abbreviated New Drug Application for Fentanyl Transdermal System
in 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr strengths.
Food and Drug Administration (FDA) has granted final approval for Mylan Technologies' Supplemental Abbreviated New Drug Application for its 12 mcg/hr Fentanyl Transdermal System
s (NYSE:MYL) patent litigation with Johnson & Johnson ("J&J") about Mylan's fentanyl transdermal system
, Vice Chairman and CEO Robert J.
Company Updates Expectations for Fentanyl Transdermal System
5% on July 26 fully anticipating additional competition for its fentanyl transdermal system
Noven has completed bioequivalence studies comparing its developmental fentanyl transdermal system
to Duragesic(R), a Schedule II opioid analgesic transdermal system for chronic pain distributed by Janssen Pharmaceutica, L.